Answers are grounded in this paper and cite their sources.
Triple-negative breast cancer remains refractory to conventional chemotherapy, driving demand for selective metallopharmaceuticals that trigger immunogenic cell death and convert immune-desert “cold” tumors into immune-vulnerable “hot” tumors. Here, we delineate the in vitro efficacy and regulated cell death (RCD) landscape of compound 2 [RuCl(p-cymene)(4′-methoxyflavonol)], a half-sandwich Ru(II)–arene flavonol complex assembled from 3-hydroxy-4′-methoxyflavone and dichloro(p-cymene)ruthenium(II) dimer. Under 24 h CCK-8 assays, compound 2 potently inhibited aggressive breast cancer models—human MDA-MB-231 IC50 37.6 μM and murine 4T1 IC50 26.1 μM—while sparing non-malignant human mammary epithelial H184B5F5/M10 (IC50 72.6 μM, SI 1.9) and mouse embryonic fibroblasts (IC50 41.3 μM, SI 1.6), showing activity comparable to cisplatin (IC50 41.2 μM in MDA-MB-231) and superior to free ligand + Ru-dimer mixture (IC50 108.9 μM). Compound 2 exhibited favorable physiological stability and enhanced stability under mildly acidic, tumor-mimetic conditions, supporting a tumor-retentive prodrug behavior. CTS-RCDP multiparametric flow cytometry revealed a multimodal death network predominantly driven by pyroptosis (51.7% in MDA-MB-231, 40.1% in 4T1), accompanied by apoptosis, validated by caspase-1/-3 colorimetric assays (3.2-fold/2.4-fold increase, p < 0.01). This was coupled with pronounced elevation of mitochondrial mass and mtROS. Collectively, compound 2 emerges as a selective Ru-flavonol complex that drives pyroptosis-dominant cell death, a lytic, pro-inflammatory modality recognized to reprogram immunologically “cold” tumors into immune-vulnerable “hot” lesions.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: